MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.460
-0.040
-1.14%
Closed 16:00 11/26 EST
OPEN
3.500
PREV CLOSE
3.500
HIGH
3.540
LOW
3.390
VOLUME
523.19K
TURNOVER
--
52 WEEK HIGH
6.15
52 WEEK LOW
1.700
MARKET CAP
249.34M
P/E (TTM)
-4.1899
1D
5D
1M
3M
1Y
5Y
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases,...
AccessWire · 11/11 13:05
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for...
AccessWire · 11/08 13:00
Pieris Pharmaceuticals, Servier Dose First Patient in Phase 1/2 Trial of Solid Tumor Treatment
MT Newswires · 11/08 11:12
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Misses Revenue Estimates
Zacks.com · 11/02 13:05
BRIEF-Pieris Pharmaceuticals Inc Says QTRLY Loss Per Share $0.24
reuters.com · 11/02 11:55
Pieris Pharmaceuticals Q3 EPS $(0.24), Inline, Sales $4.06M Miss $5.32M Estimate
Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 7.69 percent increase over losses of $(0.26) per share from the same period last
Benzinga · 11/02 11:43
Pieris Pharmaceuticals EPS in-line, misses on revenue
Pieris Pharmaceuticals (NASDAQ:PIRS): Q3 GAAP EPS of -$0.24 in-line. Revenue of $4.05M (+37.8% Y/Y) misses by $1.27M. Press Release
Seekingalpha · 11/02 11:32
-- Earnings Flash (PIRS) PIERIS PHARMACEUTICALS Posts Q3 Revenue $4.1M
MT Newswires · 11/02 07:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PIRS. Analyze the recent business situations of Pieris Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PIRS stock price target is 8.50 with a high estimate of 9.00 and a low estimate of 8.00.
High9.00
Average8.50
Low8.00
Current 3.460
EPS
Actual
Estimate
-0.23-0.17-0.12-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 127
Institutional Holdings: 36.66M
% Owned: 50.87%
Shares Outstanding: 72.06M
TypeInstitutionsShares
Increased
17
2.51M
New
24
6.47M
Decreased
17
2.03M
Sold Out
21
1.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
President/Chief Executive Officer/Director
Stephen Yoder
Chief Financial Officer/Senior Vice President
Thomas Bures
Senior Vice President/Chief Scientific Officer
Hitto Kaufmann
Senior Vice President/General Counsel/Secretary
Ahmed Mousa
Senior Vice President
Tim Demuth
Senior Vice President
Shane Olwill
Independent Director
Ann Barbier
Independent Director
Peter Kiener
Independent Director
Christopher Kiritsy
Independent Director
Michael Richman
Independent Director
Maya Said
Independent Director
Matthew Sherman
No Data
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein specific for 4-1BB.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.